1
|
Xue Y, Savchenko AI, Agnew-Francis KA, Miles JA, Holt T, Lu H, Chow S, Forster PI, Boyle GM, Ross BP, Fischer K, Kutateladze AG, Williams CM. seco-Pregnane Glycosides from Australian Caustic Vine ( Cynanchum viminale subsp. australe). J Nat Prod 2023; 86:490-497. [PMID: 36795946 DOI: 10.1021/acs.jnatprod.2c01037] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Abstract
Cynanchum viminale subsp. australe, more commonly known as caustic vine, is a leafless succulent that grows in the northern arid zone of Australia. Toxicity toward livestock has been reported for this species, along with use in traditional medicine and its potential anticancer activity. Disclosed herein are novel seco-pregnane aglycones cynavimigenin A (5) and cynaviminoside A (6), together with new pregnane glycosides cynaviminoside B (7) and cynavimigenin B (8). Cynavimigenin B (8) contains an unprecedented 7-oxobicyclo[2.2.1]heptane moiety in the seco-pregnane series, likely arising from a pinacol-type rearrangement. Interestingly, these isolates displayed only limited cytotoxicity in cancer and normal human cell lines, in addition to low activity against acetylcholinesterase and Sarcoptes scabiei bioassays, suggesting that 5-8 are not associated with the reported toxicity of this plant species.
Collapse
Affiliation(s)
- Yongbo Xue
- School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, 4072 Queensland, Australia
- School of Pharmaceutical Sciences (Shenzhen), Sun Yat-Sen University, Shenzhen, 518107, People's Republic of China
| | - Andrei I Savchenko
- School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, 4072 Queensland, Australia
| | - Kylie A Agnew-Francis
- School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, 4072 Queensland, Australia
| | - Jared A Miles
- School of Pharmacy, University of Queensland, Brisbane, 4072 Queensland, Australia
| | - Tina Holt
- Department of Chemistry and Biochemistry, University of Denver, Denver, Colorado 80208, United States
| | - Hieng Lu
- QIMR Berghofer Medical Research Institute, PO Royal Brisbane Hospital, Brisbane, 4029 Queensland, Australia
| | - Sharon Chow
- School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, 4072 Queensland, Australia
| | - Paul I Forster
- Department of Environment and Science, Brisbane Botanic Gardens, Mt Coot-tha, Queensland Herbarium, Brisbane, 4066 Queensland, Australia
| | - Glen M Boyle
- QIMR Berghofer Medical Research Institute, PO Royal Brisbane Hospital, Brisbane, 4029 Queensland, Australia
| | - Benjamin P Ross
- School of Pharmacy, University of Queensland, Brisbane, 4072 Queensland, Australia
| | - Katja Fischer
- QIMR Berghofer Medical Research Institute, PO Royal Brisbane Hospital, Brisbane, 4029 Queensland, Australia
| | - Andrei G Kutateladze
- Department of Chemistry and Biochemistry, University of Denver, Denver, Colorado 80208, United States
| | - Craig M Williams
- School of Chemistry and Molecular Biosciences, University of Queensland, Brisbane, 4072 Queensland, Australia
| |
Collapse
|
2
|
Miles JA, Ng JH, Sreenivas BY, Courageux C, Igert A, Dias J, McGeary RP, Brazzolotto X, Ross BP. Cover Image. Chem Biol Drug Des 2021. [DOI: 10.1111/cbdd.13717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
3
|
Banun VJ, Rewatkar P, Chaudhary Z, Qu Z, Janjua T, Patil A, Wu Y, Ta HT, Bansal N, Miles JA, Ross BP, Kumeria T, Popat A. Protein Nanoparticles for Enhanced Oral Delivery of Coenzyme-Q10: in Vitro and in Silico Studies. ACS Biomater Sci Eng 2021. [PMID: 33617219 DOI: 10.1021/acsbiomaterials.0c01354] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Coenzyme-Q10 (CoQ10) is a hydrophobic benzoquinone with antioxidant and anti-inflammatory properties. It is known to reduce oxidative stress in various health conditions. However, due to the low solubility, permeability, stability, and poor oral bioavailability, the oral dose of CoQ10 required for the desired therapeutic effect is very high. In the present study, CoQ10 is encapsulated into two milk derived proteins β-lactoglobulin and lactoferrin (BLG and LF) to produce self-assembled nanostructures of around 100-300 nm with high encapsulation efficiency (5-10% w/w). Both CoQ10-BLG and CoQ10-LF nanoparticles (NPs) significantly improved the aqueous solubility of CoQ10 60-fold and 300-fold, compared to CoQ10 alone, which hardly dissolves in water. Insight into the difference in solubility enhancement between BLG and LF was obtained using in silico modeling, which predicted that LF possesses multiple prospective CoQ10 binding sites, potentially enabling greater loading of CoQ10 on LF compared to BLG, which was predicted to be less capable of binding CoQ10. At pH 7.4, CoQ10-LF NPs showed a burst release between 30 min and 2 h then plateaued at 12 h with 30% of the total drug released over 48 h. However, pure CoQ10-BLG and pure CoQ10 had a significantly lower release rate with less than 15% and 8% cumulative release in 48 h, respectively. Most importantly, both BLG and LF NPs significantly improved CoQ10 permeability compared to the pre-dissolved drug across the Caco-2 monolayer with up to 2.5-fold apparent permeability enhancement for CoQ10-LF-further confirming the utility of this nanoencapsulation approach. Finally, in murine macrophage cells (J774A.1), CoQ10-LF NPs displayed significantly higher anti-ROS properties compared to CoQ10 (predissolved in DMSO) without affecting the cell viability. This study paves the way in improving oral bioavailability of poorly soluble drugs and nutraceuticals using milk-based self-assembled nanoparticles.
Collapse
Affiliation(s)
- Vanessa Jane Banun
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Prarthana Rewatkar
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Zanib Chaudhary
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Zhi Qu
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Taskeen Janjua
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Anuja Patil
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Yuao Wu
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, Australia.,Queensland Micro- and Nanotechnology Centre, Griffith University, Brisbane, Queensland, Australia
| | - Hang T Ta
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia.,Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Queensland, Australia.,Queensland Micro- and Nanotechnology Centre, Griffith University, Brisbane, Queensland, Australia.,School of Environment and Science, Griffith University, Brisbane, Queensland, Australia
| | - Nidhi Bansal
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia.,School of Agriculture and Food Sciences, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Jared A Miles
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Benjamin P Ross
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Tushar Kumeria
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia.,School of Materials Science and Engineering, The University of New South Wales, Sydney, New South Wales NSW2052, Australia
| | - Amirali Popat
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia.,Mater Research Institute, The University of Queensland, Translational Research Institute, 37 Kent St, Woolloongabba, Queensland 4102, Australia
| |
Collapse
|
4
|
Raza A, Miles JA, Sime FB, Ross BP, Roberts JA, Popat A, Kumeria T, Falconer JR. PLGA encapsulated γ-cyclodextrin-meropenem inclusion complex formulation for oral delivery. Int J Pharm 2021; 597:120280. [PMID: 33540004 DOI: 10.1016/j.ijpharm.2021.120280] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2020] [Revised: 01/07/2021] [Accepted: 01/08/2021] [Indexed: 12/25/2022]
Abstract
Meropenem (MER) is one of the last resort antibiotics used to treat resistant bacterial infections. However, the clinical effectiveness of MER is hindered due to chemical instability in aqueous solution and gastric pH, and short plasma half-life. Herein, a novel multi-material delivery system based on γ-cyclodextrin (γ-CD) and poly lactic-co-glycolic acid (PLGA) is demonstrated to overcome these challenges. MER showed a saturated solubility of 14 mg/100 mL in liquid CO2 and later it was loaded into γ-CD to form the inclusion complex using the liquid CO2 method. The γ-CD and MER inclusion complex (MER-γ-CD) was encapsulated into PLGA by the well-established double emulsion solvent evaporation method. The formation of the inclusion complex was confirmed using FTIR, XRD, DSC, SEM, and 1H NMR and docking study. Further, MER-γ-CD loaded PLGA nanoparticles (MER-γ-CD NPs) were characterized by SEM, DLS, and FTIR. The drug loading and entrapment efficiency for MER-γ-CD were 21.9 and 92. 2% w/w, respectively. However, drug loading and entrapment efficiency of MER-γ-CD NPs was significantly lower at up to 3.6 and 42.1% w/w, respectively. In vitro release study showed that 23.6 and 27.4% of active (non-degraded drug) and total drug (both degraded and non-degraded drug) were released from MER-γ-CD NPs in 8 h, respectively. The apparent permeability coefficient (Papp) (A to B) for MER, MER-γ-CD, and MER-γ-CD NPs were 2.63 × 10-6 cm/s, 2.81 × 10-6 cm/s, and 2.92 × 10-6 cm/s, respectively. For secretory transport, the Papp (B to A) were 1.47 × 10-6 cm/s, 1.53 × 10-6 cm/s, and 1.58 × 10-6 cm/s for MER, MER-γ-CD and MER-γ-CD NPs, respectively. Finally, the MER-γ-CD inclusion complex and MER-γ-CD NPs retained MER's antibacterial activities against Staphylococcus aureus and Pseudomonas aeruginosa. Overall, this work demonstrates the significance of MER-γ-CD NPs to protect MER from gastric pH with controlled drug release, while retaining MER's antibacterial activity.
Collapse
Affiliation(s)
- Aun Raza
- School of Pharmacy, The University of Queensland, Woolloongabba 4102, Australia; Centre for Translational Anti-infective Pharmacodynamics, School of Pharmacy, The University of Queensland, Woolloongabba 4102, QLD, Australia
| | - Jared A Miles
- School of Pharmacy, The University of Queensland, Woolloongabba 4102, Australia
| | - Fekade Bruck Sime
- School of Pharmacy, The University of Queensland, Woolloongabba 4102, Australia; Centre for Translational Anti-infective Pharmacodynamics, School of Pharmacy, The University of Queensland, Woolloongabba 4102, QLD, Australia
| | - Benjamin P Ross
- School of Pharmacy, The University of Queensland, Woolloongabba 4102, Australia
| | - Jason A Roberts
- School of Pharmacy, The University of Queensland, Woolloongabba 4102, Australia; Centre for Translational Anti-infective Pharmacodynamics, School of Pharmacy, The University of Queensland, Woolloongabba 4102, QLD, Australia; Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane 4029, QLD, Australia; Department of Pharmacy, Royal Brisbane and Women's Hospital, Brisbane 4029, QLD, Australia
| | - Amirali Popat
- School of Pharmacy, The University of Queensland, Woolloongabba 4102, Australia; Mucosal Diseases Group, Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent St, Woolloongabba, QLD 4102, Australia.
| | - Tushar Kumeria
- School of Pharmacy, The University of Queensland, Woolloongabba 4102, Australia; School of Materials Science and Engineering, The University of New South Wales, Sydney NSW-2052, Australia.
| | - James R Falconer
- School of Pharmacy, The University of Queensland, Woolloongabba 4102, Australia.
| |
Collapse
|
5
|
Miles JA, Ng JH, Sreenivas BY, Courageux C, Igert A, Dias J, McGeary RP, Brazzolotto X, Ross BP. Discovery of drug-like acetylcholinesterase inhibitors by rapid virtual screening of a 6.9 million compound database. Chem Biol Drug Des 2021; 97:1048-1058. [PMID: 33455074 DOI: 10.1111/cbdd.13825] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2020] [Revised: 01/08/2021] [Accepted: 01/10/2021] [Indexed: 12/13/2022]
Abstract
Cholinesterase inhibitors remain the mainstay of Alzheimer's disease treatment, and the search for new inhibitors with better efficacy and side effect profiles is ongoing. Virtual screening (VS) is a powerful technique for searching large compound databases for potential hits. This study used a sequential VS workflow combining ligand-based VS, molecular docking and physicochemical filtering to screen for central nervous system (CNS) drug-like acetylcholinesterase inhibitors (AChEIs) amongst the 6.9 million compounds of the CoCoCo database. Eleven in silico hits were initially selected, resulting in the discovery of an AChEI with a Ki of 3.2 µM. In vitro kinetics and in silico molecular dynamics experiments informed the selection of an additional seven analogues. This led to the discovery of two further AChEIs, with Ki values of 2.9 µM and 0.65 µM. All three compounds exhibited reversible, mixed inhibition of acetylcholinesterase. Importantly, the in silico physicochemical filter facilitated the discovery of CNS drug-like compounds, such that all three inhibitors displayed high in vitro blood-brain barrier model permeability.
Collapse
Affiliation(s)
- Jared A Miles
- School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia
| | - Jia Hui Ng
- School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia
| | - B Yogi Sreenivas
- School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia
| | - Charlotte Courageux
- Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées, Brétigny sur Orge, France
| | - Alexandre Igert
- Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées, Brétigny sur Orge, France
| | - José Dias
- Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées, Brétigny sur Orge, France
| | - Ross P McGeary
- School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD, Australia
| | - Xavier Brazzolotto
- Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées, Brétigny sur Orge, France
| | - Benjamin P Ross
- School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia
| |
Collapse
|
6
|
Abstract
Alzheimer's disease (AD) is a significant health crisis, and current treatments provide only limited benefits to cognition at the cost of serious side effects. Recently, virtual screening techniques such as ligand-based virtual screening (LBVS) and structure-based virtual screening (SBVS) have emerged as powerful drug discovery tools for identifying potential ligands of a biological target from a large database of chemical structures. The cholinesterases are an AD target particularly well suited for drug discovery using virtual screening due to their well-characterized active sites and comprehensive understanding of the structure-activity relationships of existing inhibitors. Over the last 5 years (2015-2020), at least 15 studies have used virtual screening techniques to discover potent new cholinesterase inhibitors. Herein we review how LBVS and SBVS have been applied individually or in tandem to discover novel acetylcholinesterase and butyrylcholinesterase inhibitors for AD, and highlight the need to confirm in vitro activity of screening compounds.
Collapse
Affiliation(s)
- Jared A. Miles
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Benjamin P. Ross
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| |
Collapse
|
7
|
Pujara N, Giri R, Wong KY, Qu Z, Rewatkar P, Moniruzzaman M, Begun J, Ross BP, McGuckin M, Popat A. pH - Responsive colloidal carriers assembled from β-lactoglobulin and Epsilon poly-L-lysine for oral drug delivery. J Colloid Interface Sci 2020; 589:45-55. [PMID: 33450459 DOI: 10.1016/j.jcis.2020.12.054] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 12/14/2020] [Accepted: 12/17/2020] [Indexed: 02/07/2023]
Abstract
Site specific oral delivery of many biopharmaceutical classification system (BCS) class II and IV drugs is challenging due to their poor solubility, low permeability and degradation in the gastrointestinal tract. Whilst colloidal carriers have been used to improve the bioavailability of such drugs, most nanocarriers based drug delivery systems suffer from multiple disadvantages, including low encapsulation efficiency (liposomes, polymeric nanoparticles), complex synthesis methods (silica, silicon-based materials) and poorly understood biodegradability (inorganic nanoparticles). Herein, a novel pH responsive nanocolloids were self-assembled using natural compounds such as bovine β-lactoglobulin (BLG) and succinylated β-lactoglobulin (succ. BLG) cross-linked with epsilon poly l-lysine (BCEP and BCP), and found to possess high loading capacity, high aqueous solubility and site-specific oral delivery of a poorly soluble nutraceutical (curcumin), improving its physicochemical properties and biological activity in-vitro and ex-vivo. Our optimized synthesis formed colloids of around 200 nm which were capable of encapsulating curcumin with ~100% encapsulation efficiency and ~10% w/w drug loading. By forming nanocomplexes of curcumin with BLG and succ. BLG, the aqueous solubility of curcumin was markedly increased by ~160-fold and ~86-fold, respectively. Encapsulation with BLG increased the solubility, whereas succ. BLG prevent release of encapsulated curcumin when subjected to gastric fluids as it is resistant to breakdown on exposure to pepsin at acidic pH. In conditions mimicking the small intestine, Succ. BLG was more soluble resulting in sustained release of the encapsulated drug at pH 7.4. Additionally, crosslinking succ. BLG with E-PLL significantly enhanced curcumin's permeability in an in-vitro Caco-2 cell monolayer model compared to curcumin solution (dissolved in 1% DMSO), or non-crosslinked BLG/succ. and BLG. In a mouse-derived intestinal epithelial 3D organoid culture stimulated with IL-1β, BLG-CUR and crosslinked BCEP nanoparticles reduced the production of inflammatory cytokines and chemokines such as Tnfα and Cxcl10 more than curcumin solution or suspension while these nanoparticles were non-toxic to organoids. Overall this work demonstrates the promise of nutraceutical-based hybrid self-assembled colloidal system to protect hydrophobic drugs from harsh gastrointestinal conditions and improve their solubility, dissolution, permeability and biological activity.
Collapse
Affiliation(s)
- Naisarg Pujara
- School of Pharmacy, The University of Queensland, Brisbane, QLD 4102, Australia
| | - Rabina Giri
- Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia; Inflammatory Bowel Disease Group, Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent St, Woolloongabba, QLD 4102, Australia
| | - Kuan Yau Wong
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent St, Woolloongabba, QLD 4102, Australia
| | - Zhi Qu
- School of Pharmacy, The University of Queensland, Brisbane, QLD 4102, Australia; Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent St, Woolloongabba, QLD 4102, Australia
| | - Prarthana Rewatkar
- School of Pharmacy, The University of Queensland, Brisbane, QLD 4102, Australia
| | - Md Moniruzzaman
- School of Pharmacy, The University of Queensland, Brisbane, QLD 4102, Australia; Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia; Inflammatory Bowel Disease Group, Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent St, Woolloongabba, QLD 4102, Australia
| | - Jakob Begun
- Faculty of Medicine, The University of Queensland, Brisbane, QLD 4072, Australia; Inflammatory Bowel Disease Group, Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent St, Woolloongabba, QLD 4102, Australia
| | - Benjamin P Ross
- School of Pharmacy, The University of Queensland, Brisbane, QLD 4102, Australia
| | - Michael McGuckin
- Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent St, Woolloongabba, QLD 4102, Australia; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, VIC 3010, Australia.
| | - Amirali Popat
- School of Pharmacy, The University of Queensland, Brisbane, QLD 4102, Australia; Mater Research Institute - The University of Queensland, Translational Research Institute, 37 Kent St, Woolloongabba, QLD 4102, Australia.
| |
Collapse
|
8
|
Miles JA, Kapure JS, Deora GS, Courageux C, Igert A, Dias J, McGeary RP, Brazzolotto X, Ross BP. Rapid discovery of a selective butyrylcholinesterase inhibitor using structure-based virtual screening. Bioorg Med Chem Lett 2020; 30:127609. [PMID: 33039562 DOI: 10.1016/j.bmcl.2020.127609] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2020] [Revised: 09/26/2020] [Accepted: 10/05/2020] [Indexed: 02/08/2023]
Abstract
Acetylcholinesterase inhibitors are the mainstay of Alzheimer's disease treatments, despite having only short-term symptomatic benefits and severe side effects. Selective butyrylcholinesterase inhibitors (BuChEIs) may be more effective treatments in late-stage Alzheimer's disease with fewer side effects. Virtual screening is a powerful tool for identifying potential inhibitors in large digital compound databases. This study used structure-based virtual screening combined with physicochemical filtering to screen the InterBioScreen and Maybridge databases for novel selective BuChEIs. The workflow rapidly identified 22 potential hits in silico, resulting in the discovery of a human BuChEI with low-micromolar potency in vitro (IC50 2.4 µM) and high selectivity for butyrylcholinesterase over acetylcholinesterase. The compound was a rapidly reversible BuChEI with mixed-model in vitro inhibition kinetics. The binding interactions were investigated using in silico molecular dynamics and by developing structure-activity relationships using nine analogues. The compound also displayed high permeability in an in vitro model of the blood-brain barrier.
Collapse
Affiliation(s)
- Jared A Miles
- The University of Queensland, School of Pharmacy, Brisbane, Queensland 4072, Australia
| | - Jeevak S Kapure
- The University of Queensland, School of Pharmacy, Brisbane, Queensland 4072, Australia
| | - Girdhar Singh Deora
- The University of Queensland, School of Pharmacy, Brisbane, Queensland 4072, Australia; Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia
| | - Charlotte Courageux
- Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées, 91223 Brétigny sur Orge, France
| | - Alexandre Igert
- Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées, 91223 Brétigny sur Orge, France
| | - José Dias
- Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées, 91223 Brétigny sur Orge, France
| | - Ross P McGeary
- The University of Queensland, School of Chemistry and Molecular Biosciences, Brisbane, Queensland 4072, Australia
| | - Xavier Brazzolotto
- Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées, 91223 Brétigny sur Orge, France
| | - Benjamin P Ross
- The University of Queensland, School of Pharmacy, Brisbane, Queensland 4072, Australia.
| |
Collapse
|
9
|
Pujara N, Wong KY, Qu Z, Wang R, Moniruzzaman M, Rewatkar P, Kumeria T, Ross BP, McGuckin M, Popat A. Oral Delivery of β-Lactoglobulin-Nanosphere-Encapsulated Resveratrol Alleviates Inflammation in Winnie Mice with Spontaneous Ulcerative Colitis. Mol Pharm 2020; 18:627-640. [PMID: 32437160 DOI: 10.1021/acs.molpharmaceut.0c00048] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Resveratrol (RES) is a nutraceutical with promising anti-inflammatory properties for the treatment of inflammatory bowel diseases (IBD). However, the clinical effectiveness of resveratrol as an oral anti-inflammatory agent is hindered by its extremely poor solubility and poor stability. In this study, we encapsulated resveratrol in β-lactoglobulin (BLG) nanospheres and systematically analyzed their formulation parameters in vitro followed by a thorough in vivo anti-inflammatory testing in a highly specialized spontaneous murine UC model (Winnie mice model). Complexation of resveratrol with BLG increased the aqueous solubility of resveratrol by ≈1.7 times with 10% w/w loading. Additionally, the in vitro dissolution of resveratrol from the particles was found to be higher compared to resveratrol alone, resulting in >90% resveratrol dissolution in ∼8 h. The anti-inflammatory activity of resveratrol was examined for the first time in Winnie mice, a mouse model that closely represents the clinical signs of IBD. At a 50 mg/kg oral dose for 2 weeks, BLG-RES significantly improved both % body weight and disease activity index (DAI), compared to free resveratrol in Winnie mice. Importantly, histological evaluations revealed a similar trend with striking improvement in the pathology of the colon via an increase in goblet cell numbers and recovery of colonic epithelium. BLG-RES significantly increased the expression level of cytokine interleukin-10 (Il10), which confirms the reduction in inflammation potentially because of the increased dissolution and stability of resveratrol by complexation with BLG. This comprehensive study demonstrates the effectiveness of biocompatible nanomaterials such as BLG in oral delivery of poorly soluble anti-inflammatory molecules such as resveratrol in the treatment of IBD.
Collapse
Affiliation(s)
- Naisarg Pujara
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Kuan Yau Wong
- Mucosal Diseases Group, Mater Research Institute, The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland 4102, Australia
| | - Zhi Qu
- Mucosal Diseases Group, Mater Research Institute, The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland 4102, Australia
| | - Ran Wang
- Mucosal Diseases Group, Mater Research Institute, The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland 4102, Australia
| | - Md Moniruzzaman
- Mucosal Diseases Group, Mater Research Institute, The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland 4102, Australia
| | - Prarthana Rewatkar
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Tushar Kumeria
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Benjamin P Ross
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Michael McGuckin
- Mucosal Diseases Group, Mater Research Institute, The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland 4102, Australia.,Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria 3010, Australia
| | - Amirali Popat
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia.,Mucosal Diseases Group, Mater Research Institute, The University of Queensland, Translational Research Institute, 37 Kent Street, Woolloongabba, Queensland 4102, Australia
| |
Collapse
|
10
|
Azimi I, Stevenson RJ, Zhang X, Meizoso-Huesca A, Xin P, Johnson M, Flanagan JU, Chalmers SB, Yoast RE, Kapure JS, Ross BP, Vetter I, Ashton MR, Launikonis BS, Denny WA, Trebak M, Monteith GR. A new selective pharmacological enhancer of the Orai1 Ca 2+ channel reveals roles for Orai1 in smooth and skeletal muscle functions. ACS Pharmacol Transl Sci 2020; 3:135-147. [PMID: 32190822 DOI: 10.1021/acsptsci.9b00081] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Store operated calcium (Ca2+) entry is an important homeostatic mechanism in cells, whereby the release of Ca2+ from intracellular endoplasmic reticulum stores triggers the activation of a Ca2+ influx pathway. Mediated by Orai1, this Ca2+ influx has specific and essential roles in biological processes as diverse as lactation to immunity. Although pharmacological inhibitors of this Ca2+ influx mechanism have helped to define the role of store operated Ca2+ entry in many cellular events, the lack of isoform specific modulators and activators of Orai1 has limited our full understanding of these processes. Here we report the identification and synthesis of an Orai1 activity enhancer that concurrently potentiated Orai1 Ca2+ -dependent inactivation (CDI). This unique enhancer of Orai1 had only a modest effect on Orai3 with weak inhibitory effects at high concentrations in intact MCF-7 breast cancer cells. The Orai1 enhancer heightened vascular smooth muscle cell migration induced by platelet-derived growth factor and the unique store operated Ca2+ entry pathway present in skeletal muscle cells. These studies show that IA65 is an exemplar for the translation and development of Orai isoform selective agents. The ability of IA65 to activate CDI demonstrates that agents can be developed that can enhance Orai1-mediated Ca2+ influx but avoid the cytotoxicity associated with sustained Orai1 activation. IA65 and/or future analogues with similar Orai1 and CDI activating properties could be fine tuners of physiological processes important in specific disease states, such as cellular migration and immune cell function.
Collapse
Affiliation(s)
- Iman Azimi
- Division of Pharmacy, College of Health and Medicine, University of Tasmania, Hobart, Tasmania 7001, Australia
| | - Ralph J Stevenson
- Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, 1142, New Zealand
| | - Xuexin Zhang
- Department of Cellular and Molecular Physiology, and Pennsylvania State Cancer Institute. The Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA
| | - Aldo Meizoso-Huesca
- School of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia
| | - Ping Xin
- Department of Cellular and Molecular Physiology, and Pennsylvania State Cancer Institute. The Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA
| | - Martin Johnson
- Department of Cellular and Molecular Physiology, and Pennsylvania State Cancer Institute. The Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA
| | - Jack U Flanagan
- Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, 1142, New Zealand
| | - Silke B Chalmers
- School of Pharmacy, The University of Queensland, Brisbane 4072, Queensland, Australia
| | - Ryan E Yoast
- Department of Cellular and Molecular Physiology, and Pennsylvania State Cancer Institute. The Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA
| | - Jeevak S Kapure
- School of Pharmacy, The University of Queensland, Brisbane 4072, Queensland, Australia
| | - Benjamin P Ross
- School of Pharmacy, The University of Queensland, Brisbane 4072, Queensland, Australia
| | - Irina Vetter
- School of Pharmacy, The University of Queensland, Brisbane 4072, Queensland, Australia.,IMB Centre for Pain Research, Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, 4072, Australia
| | - Mark R Ashton
- UniQuest Pty Ltd, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Bradley S Launikonis
- School of Biomedical Sciences, The University of Queensland, Brisbane, QLD 4072, Australia
| | - William A Denny
- Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Auckland, 1142, New Zealand
| | - Mohamed Trebak
- Department of Cellular and Molecular Physiology, and Pennsylvania State Cancer Institute. The Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA
| | - Gregory R Monteith
- School of Pharmacy, The University of Queensland, Brisbane 4072, Queensland, Australia.,Mater Research Institute, Translational Research Institute, The University of Queensland, Brisbane 4102, Queensland, Australia
| |
Collapse
|
11
|
Kamato D, Do BH, Osman N, Ross BP, Mohamed R, Xu S, Little PJ. Smad linker region phosphorylation is a signalling pathway in its own right and not only a modulator of canonical TGF-β signalling. Cell Mol Life Sci 2020; 77:243-251. [PMID: 31407020 PMCID: PMC11104920 DOI: 10.1007/s00018-019-03266-3] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2019] [Revised: 07/16/2019] [Accepted: 08/05/2019] [Indexed: 01/01/2023]
Abstract
Transforming growth factor (TGF)-β signalling pathways are intensively investigated because of their diverse association with physiological and pathophysiological states. Smad transcription factors are the key mediators of TGF-β signalling. Smads can be directly phosphorylated in the carboxy terminal by the TGF-β receptor or in the linker region via multiple intermediate serine/threonine kinases. Growth factors in addition to hormones and TGF-β can activate many of the same kinases which can phosphorylate the Smad linker region. Historically, Smad linker region phosphorylation was shown to prevent nuclear translocation of Smads and inhibit TGF-β signalling pathways; however, it was subsequently shown that Smad linker region phosphorylation can be a driver of gene expression. This review will cover the signalling pathways of Smad linker region phosphorylation that drive the expression of genes involved in pathology and pathophysiology. The role of Smad signalling in cell biology is expanding rapidly beyond its role in TGF-β signalling and many signalling paradigms need to be re-evaluated in terms of Smad involvement.
Collapse
Affiliation(s)
- Danielle Kamato
- Pharmacy Australia Centre of Excellence, School of Pharmacy, The University of Queensland, 20 Cornwall Street, Woolloongabba, QLD, 4102, Australia.
- Department of Pharmacy, Xinhua College of Sun Yat-Sen University, Tianhe District, Guangzhou, 510520, China.
| | - Bich Hang Do
- Faculty of Pharmacy, Ton Duc Thang University, Ho Chi Minh City, 700000, Vietnam
| | - Narin Osman
- School of Medical Sciences, RMIT University, Bundoora, VIC, 3083, Australia
- Department of Immunology, Monash University, Melbourne, VIC, 3004, Australia
| | - Benjamin P Ross
- Pharmacy Australia Centre of Excellence, School of Pharmacy, The University of Queensland, 20 Cornwall Street, Woolloongabba, QLD, 4102, Australia
| | - Raafat Mohamed
- Pharmacy Australia Centre of Excellence, School of Pharmacy, The University of Queensland, 20 Cornwall Street, Woolloongabba, QLD, 4102, Australia
- Department of Basic Sciences, College of Dentistry, University of Mosul, Mosul, Iraq
| | - Suowen Xu
- Department of Medicine, Aab Cardiovascular Research Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
| | - Peter J Little
- Pharmacy Australia Centre of Excellence, School of Pharmacy, The University of Queensland, 20 Cornwall Street, Woolloongabba, QLD, 4102, Australia
- Department of Pharmacy, Xinhua College of Sun Yat-Sen University, Tianhe District, Guangzhou, 510520, China
| |
Collapse
|
12
|
Abeer MM, Meka AK, Pujara N, Kumeria T, Strounina E, Nunes R, Costa A, Sarmento B, Hasnain SZ, Ross BP, Popat A. Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide. Pharmaceutics 2019; 11:E418. [PMID: 31430872 PMCID: PMC6723263 DOI: 10.3390/pharmaceutics11080418] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2019] [Revised: 08/04/2019] [Accepted: 08/15/2019] [Indexed: 01/17/2023] Open
Abstract
Type 2 diabetes makes up approximately 85% of all diabetic cases and it is linked to approximately one-third of all hospitalisations. Newer therapies with long-acting biologics such as glucagon-like peptide-1 (GLP-1) analogues have been promising in managing the disease, but they cannot reverse the pathology of the disease. Additionally, their parenteral administration is often associated with high healthcare costs, risk of infections, and poor patient adherence associated with phobia of needles. Oral delivery of these compounds would significantly improve patient compliance; however, poor enzymatic stability and low permeability across the gastrointestinal tract makes this task challenging. In the present work, large pore dendritic silica nanoparticles (DSNPs) with a pore size of ~10 nm were prepared, functionalized, and optimized in order to achieve high peptide loading and improve intestinal permeation of exenatide, a GLP-1 analogue. Compared to the loading capacity of the most popular, Mobil Composition of Matter No. 41 (MCM-41) with small pores, DSNPs showed significantly high loading owing to their large and dendritic pore structure. Among the tested DSNPs, pristine and phosphonate-modified DSNPs (PDSNPs) displayed remarkable loading of 40 and 35% w/w, respectively. Furthermore, particles successfully coated with positively charged chitosan reduced the burst release of exenatide at both pH 1.2 and 6.8. Compared with free exenatide, both chitosan-coated and uncoated PDSNPs enhanced exenatide transport through the Caco-2 monolayer by 1.7 fold. Interestingly, when a triple co-culture model of intestinal permeation was used, chitosan-coated PDSNPs performed better compared to both PDSNPs and free exenatide, which corroborated our hypothesis behind using chitosan to interact with mucus and improve permeation. These results indicate the emerging role of large pore silica nanoparticles as promising platforms for oral delivery of biologics such as exenatide.
Collapse
Affiliation(s)
| | - Anand Kumar Meka
- School of Pharmacy, The University of Queensland, Brisbane QLD 4072, Australia
| | - Naisarg Pujara
- School of Pharmacy, The University of Queensland, Brisbane QLD 4072, Australia
| | - Tushar Kumeria
- School of Pharmacy, The University of Queensland, Brisbane QLD 4072, Australia
- Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba QLD 4102, Australia
| | - Ekaterina Strounina
- Center for Advanced Imaging, The University of Queensland, Brisbane QLD 4072, Australia
| | - Rute Nunes
- Instituto de Investigação e Inovação em Saúde (I3S), University of Porto, Rua Alfredo Allen, 208, 4200-135 Porto, Portugal
- Instituto de Engenharia Biomédica (INEB), University of Porto, Rua Alfredo Allen, 208, 4200-135 Porto, Portugal
| | - Ana Costa
- Instituto de Investigação e Inovação em Saúde (I3S), University of Porto, Rua Alfredo Allen, 208, 4200-135 Porto, Portugal
- Instituto de Engenharia Biomédica (INEB), University of Porto, Rua Alfredo Allen, 208, 4200-135 Porto, Portugal
| | - Bruno Sarmento
- Instituto de Investigação e Inovação em Saúde (I3S), University of Porto, Rua Alfredo Allen, 208, 4200-135 Porto, Portugal
- Instituto de Engenharia Biomédica (INEB), University of Porto, Rua Alfredo Allen, 208, 4200-135 Porto, Portugal
- CESPU, Instituto de Investigação e Formação Avançada em Ciências e Tecnologias da Saúde, Rua Central de Gandra, 1317, 4585-116 Gandra, Portugal
| | - Sumaira Z Hasnain
- Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba QLD 4102, Australia
- Australian Infectious Disease Research Centre-The University of Queensland Building 76 Room 155 Cooper Road, St. Lucia QLD 4067, Australia
| | - Benjamin P Ross
- School of Pharmacy, The University of Queensland, Brisbane QLD 4072, Australia
| | - Amirali Popat
- School of Pharmacy, The University of Queensland, Brisbane QLD 4072, Australia.
- Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba QLD 4102, Australia.
| |
Collapse
|
13
|
Zhang S, Sakuma M, Deora GS, Levy CW, Klausing A, Breda C, Read KD, Edlin CD, Ross BP, Wright Muelas M, Day PJ, O’Hagan S, Kell DB, Schwarcz R, Leys D, Heyes DJ, Giorgini F, Scrutton NS. A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites. Commun Biol 2019; 2:271. [PMID: 31372510 PMCID: PMC6656724 DOI: 10.1038/s42003-019-0520-5] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Accepted: 06/28/2019] [Indexed: 12/16/2022] Open
Abstract
Dysregulation of the kynurenine pathway (KP) leads to imbalances in neuroactive metabolites associated with the pathogenesis of several neurodegenerative disorders, including Huntington's disease (HD). Inhibition of the enzyme kynurenine 3-monooxygenase (KMO) in the KP normalises these metabolic imbalances and ameliorates neurodegeneration and related phenotypes in several neurodegenerative disease models. KMO is thus a promising candidate drug target for these disorders, but known inhibitors are not brain permeable. Here, 19 new KMO inhibitors have been identified. One of these (1) is neuroprotective in a Drosophila HD model but is minimally brain penetrant in mice. The prodrug variant (1b) crosses the blood-brain barrier, releases 1 in the brain, thereby lowering levels of 3-hydroxykynurenine, a toxic KP metabolite linked to neurodegeneration. Prodrug 1b will advance development of targeted therapies against multiple neurodegenerative and neuroinflammatory diseases in which KP likely plays a role, including HD, Alzheimer's disease, and Parkinson's disease.
Collapse
Affiliation(s)
- Shaowei Zhang
- Manchester Institute of Biotechnology and School of Chemistry, The University of Manchester, Manchester, M1 7DN UK
| | - Michiyo Sakuma
- Manchester Institute of Biotechnology and School of Chemistry, The University of Manchester, Manchester, M1 7DN UK
| | - Girdhar S. Deora
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072 Australia
| | - Colin W. Levy
- Manchester Institute of Biotechnology and School of Chemistry, The University of Manchester, Manchester, M1 7DN UK
| | - Alex Klausing
- Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228 USA
| | - Carlo Breda
- Department of Genetics and Genome Biology, University of Leicester, Leicester, LE1 7RH UK
| | - Kevin D. Read
- Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, Scotland DD1 5EH UK
| | | | - Benjamin P. Ross
- School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072 Australia
| | - Marina Wright Muelas
- Manchester Institute of Biotechnology and School of Chemistry, The University of Manchester, Manchester, M1 7DN UK
| | - Philip J. Day
- Manchester Institute of Biotechnology and Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, M13 9PL UK
| | - Stephen O’Hagan
- Manchester Institute of Biotechnology and School of Chemistry, The University of Manchester, Manchester, M1 7DN UK
| | - Douglas B. Kell
- Manchester Institute of Biotechnology and School of Chemistry, The University of Manchester, Manchester, M1 7DN UK
| | - Robert Schwarcz
- Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD 21228 USA
| | - David Leys
- Manchester Institute of Biotechnology and School of Chemistry, The University of Manchester, Manchester, M1 7DN UK
| | - Derren J. Heyes
- Manchester Institute of Biotechnology and School of Chemistry, The University of Manchester, Manchester, M1 7DN UK
| | - Flaviano Giorgini
- Department of Genetics and Genome Biology, University of Leicester, Leicester, LE1 7RH UK
| | - Nigel S. Scrutton
- Manchester Institute of Biotechnology and School of Chemistry, The University of Manchester, Manchester, M1 7DN UK
| |
Collapse
|
14
|
Prokai-Tatrai K, De La Cruz DL, Nguyen V, Ross BP, Toth I, Prokai L. Brain Delivery of Thyrotropin-Releasing Hormone via a Novel Prodrug Approach. Pharmaceutics 2019; 11:E349. [PMID: 31323784 PMCID: PMC6680701 DOI: 10.3390/pharmaceutics11070349] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2019] [Revised: 07/14/2019] [Accepted: 07/16/2019] [Indexed: 12/28/2022] Open
Abstract
Using thyrotropin-releasing hormone (TRH) as a model, we explored whether synergistic combination of lipoamino acid(s) and a linker cleaved by prolyl oligopeptidase (POP) can be used as a promoiety for prodrug design for the preferential brain delivery of the peptide. A representative prodrug based on this design principle was synthesized, and its membrane affinity and in vitro metabolic stability, with or without the presence of a POP inhibitor, were studied. The in vivo formation of TRH from the prodrug construct was probed by utilizing the antidepressant effect of the peptide, as well as its ability to increase acetylcholine (ACh) synthesis and release. We found that the prototype prodrug showed excellent membrane affinity and greatly increased metabolic stability in mouse blood and brain homogenate compared to the parent peptide, yet a POP inhibitor completely prevented prodrug metabolism in brain homogenate. In vivo, administration of the prodrug triggered antidepressant-like effect, and microdialysis sampling showed greatly increased ACh release that was also antagonized upon a POP inhibitor treatment. Altogether, the obtained promising exploratory data warrant further investigations on the utility of the prodrug approach introduced here for brain-enhanced delivery of small peptides with neurotherapeutic potential.
Collapse
Affiliation(s)
- Katalin Prokai-Tatrai
- Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA.
| | - Daniel L De La Cruz
- Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
| | - Vien Nguyen
- Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
| | - Benjamin P Ross
- School of Pharmacy, The University of Queensland, Brisbane, QLD 4072, Australia
| | - Istvan Toth
- School of Chemistry & Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia
| | - Laszlo Prokai
- Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX 76107, USA
| |
Collapse
|
15
|
Lee E, Nguyen CTH, Strounina E, Davis-Poynter N, Ross BP. Structure-Activity Relationships of GAG Mimetic-Functionalized Mesoporous Silica Nanoparticles and Evaluation of Acyclovir-Loaded Antiviral Nanoparticles with Dual Mechanisms of Action. ACS Omega 2018; 3:1689-1699. [PMID: 30023813 PMCID: PMC6045419 DOI: 10.1021/acsomega.7b01662] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/28/2017] [Accepted: 01/24/2018] [Indexed: 05/20/2023]
Abstract
Mesoporous silica nanoparticles (MSNs) are drug delivery agents that are able to incorporate drugs within their pores. Furthermore, MSNs can be functionalized by attachment of bioactive ligands on their surface to enhance their activity, and nanoparticles modified with glycosaminoglycan (GAG) mimetics inhibit the entry of herpes simplex virus (HSV) into cells. In this study, structure-activity relationships of GAGs attached to MSNs were investigated in relation to HSV-1 and HSV-2, and acyclovir was loaded into the pores of MSNs. The sulfonate group was demonstrated to be essential for antiviral activity, which was enhanced by incorporating a benzene group within the ligand. Loading acyclovir into GAG mimetic-functionalized MSNs reduced the viral infection, resulting in nanoparticles that simultaneously target two distinct viral pathways, namely, inhibition of viral entry and inhibition of DNA replication.
Collapse
Affiliation(s)
- Edward
C. Lee
- School
of Pharmacy and Centre for Advanced Imaging, The University
of Queensland, Brisbane, Queensland 4072, Australia
| | - Chau T. H. Nguyen
- School
of Pharmacy and Centre for Advanced Imaging, The University
of Queensland, Brisbane, Queensland 4072, Australia
| | - Ekaterina Strounina
- School
of Pharmacy and Centre for Advanced Imaging, The University
of Queensland, Brisbane, Queensland 4072, Australia
| | - Nicholas Davis-Poynter
- Centre
for Children’s Health Research, The
University of Queensland, 46 Graham Street, Brisbane, Queensland 4101, Australia
| | - Benjamin P. Ross
- School
of Pharmacy and Centre for Advanced Imaging, The University
of Queensland, Brisbane, Queensland 4072, Australia
| |
Collapse
|
16
|
Deora GS, Kantham S, Chan S, Dighe SN, Veliyath SK, McColl G, Parat MO, McGeary RP, Ross BP. Multifunctional Analogs of Kynurenic Acid for the Treatment of Alzheimer's Disease: Synthesis, Pharmacology, and Molecular Modeling Studies. ACS Chem Neurosci 2017; 8:2667-2675. [PMID: 28825789 DOI: 10.1021/acschemneuro.7b00229] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
We report the synthesis and pharmacological investigation of analogs of the endogenous molecule kynurenic acid (KYNA) as multifunctional agents for the treatment of Alzheimer's disease (AD). Synthesized KYNA analogs were tested for their N-methyl-d-aspartate (NMDA) receptor binding, mGluR5 binding and function, acetylcholinesterase (AChE) inhibition, 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging, interference with the amyloid β peptide (Aβ) fibrillation process, and protection against Aβ-induced toxicity in transgenic Caenorhabditis elegans strain GMC101 expressing full-length Aβ42. Molecular modeling studies were also performed to predict the binding modes of most active compounds with NMDAR, mGluR5, and Aβ42. Among the synthesized analogs, 3c, 5b, and 5c emerged as multifunctional compounds that act via multiple anti-AD mechanisms including AChE inhibition, free radical scavenging, NMDA receptor binding, mGluR5 binding, inhibition of Aβ42 fibril formation, and disassembly of preformed Aβ42 fibrils. Interestingly, 5c showed protection against Aβ42-induced toxicity in transgenic C. elegans strain GMC101. Moreover, 5b and 5c displayed high permeability in an MDR1-MDCKII cell-based model of the blood-brain barrier (BBB). Compound 3b emerged with specific activity as a micromolar AChE inhibitor, however it had low permeability in the BBB model. This study highlights the opportunities that exist to develop analogs of endogenous molecules from the kynurenine pathway for therapeutic uses.
Collapse
Affiliation(s)
- Girdhar Singh Deora
- The University of Queensland, School of Pharmacy, Brisbane, Queensland 4072, Australia
| | - Srinivas Kantham
- The University of Queensland, School of Pharmacy, Brisbane, Queensland 4072, Australia
| | - Stephen Chan
- The University of Queensland, School of Pharmacy, Brisbane, Queensland 4072, Australia
| | - Satish N. Dighe
- The University of Queensland, School of Pharmacy, Brisbane, Queensland 4072, Australia
| | - Suresh K. Veliyath
- The University of Queensland, School of Pharmacy, Brisbane, Queensland 4072, Australia
| | - Gawain McColl
- The
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Victoria 3010, Australia
| | - Marie-Odile Parat
- The University of Queensland, School of Pharmacy, Brisbane, Queensland 4072, Australia
| | - Ross P. McGeary
- The University of Queensland, School of Chemistry and Molecular Biosciences, Brisbane, Queensland 4072, Australia
| | - Benjamin P. Ross
- The University of Queensland, School of Pharmacy, Brisbane, Queensland 4072, Australia
| |
Collapse
|
17
|
Kantham S, Chan S, McColl G, Miles JA, Veliyath SK, Deora GS, Dighe SN, Khabbazi S, Parat MO, Ross BP. Effect of the Biphenyl Neolignan Honokiol on Aβ 42-Induced Toxicity in Caenorhabditis elegans, Aβ 42 Fibrillation, Cholinesterase Activity, DPPH Radicals, and Iron(II) Chelation. ACS Chem Neurosci 2017. [PMID: 28650631 DOI: 10.1021/acschemneuro.7b00071] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
The biphenyl neolignan honokiol is a neuroprotectant which has been proposed as a treatment for central nervous system disorders such as Alzheimer's disease (AD). The death of cholinergic neurons in AD is attributed to multiple factors, including accumulation and fibrillation of amyloid beta peptide (Aβ) within the brain; metal ion toxicity; and oxidative stress. In this study, we used a transgenic Caenorhabditis elegans model expressing full length Aβ42 as a convenient in vivo system for examining the effect of honokiol against Aβ-induced toxicity. Furthermore, honokiol was evaluated for its ability to inhibit Aβ42 oligomerization and fibrillation; inhibit acetylcholinesterase and butyrylcholinesterase; scavenge 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals; and chelate iron(II). Honokiol displayed activity similar to that of resveratrol and (-)-epigallocatechin gallate (EGCG) in delaying Aβ42-induced paralysis in C. elegans, and it exhibited moderate-to-weak ability to inhibit Aβ42 on-pathway aggregation, inhibit cholinesterases, scavenge DPPH radicals, and chelate iron(II). Moreover, honokiol was found to be chemically stable relative to EGCG, which was highly unstable. Together with its good drug-likeness and brain availability, these results suggest that honokiol may be amenable to drug development and that the synthesis of honokiol analogues to optimize these properties should be considered.
Collapse
Affiliation(s)
- Srinivas Kantham
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Stephen Chan
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Gawain McColl
- The
Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria 3010, Australia
| | - Jared A. Miles
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Suresh Kumar Veliyath
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Girdhar Singh Deora
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Satish N. Dighe
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Samira Khabbazi
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Marie-Odile Parat
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | - Benjamin P. Ross
- School
of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| |
Collapse
|
18
|
Nguyen CTH, Webb RI, Lambert LK, Strounina E, Lee EC, Parat MO, McGuckin MA, Popat A, Cabot PJ, Ross BP. Bifunctional Succinylated ε-Polylysine-Coated Mesoporous Silica Nanoparticles for pH-Responsive and Intracellular Drug Delivery Targeting the Colon. ACS Appl Mater Interfaces 2017; 9:9470-9483. [PMID: 28252278 DOI: 10.1021/acsami.7b00411] [Citation(s) in RCA: 62] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/18/2023]
Abstract
Conventional oral drug formulations for colonic diseases require the administration of high doses of drug to achieve effective drug concentrations at the target site. However, this exposes patients to serious systemic toxicity in order to achieve efficacy. To overcome this problem, an oral drug delivery system was developed by loading a large amount (ca. 34% w/w) of prednisolone into 3-aminopropyl-functionalized mesoporous silica nanoparticles (MCM-NH2) and targeting prednisolone release to the colon by coating the nanoparticle with succinylated ε-polylysine (SPL). We demonstrate for the first time the pH-responsive ability of SPL as a "nanogate" to selectively release prednisolone in the pH conditions of the colon (pH 5.5-7.4) but not in the more acidic conditions of the stomach (pH 1.9) or small intestine (pH 5.0). In addition to targeting drug delivery to the colon, we explored whether the nanoparticles could deliver cargo intracellularly to immune cells (RAW 264.7 macrophages) and intestinal epithelial cells (LS 174T and Caco-2 adenocarcinoma cell lines). To trace uptake, MCM-NH2 were loaded with a cell membrane-impermeable dye, sulforhodamine B. The SPL-coated nanoparticles were able to deliver the dye intracellularly to RAW 264.7 macrophages and the intestinal epithelial cancer cells, which offers a highly promising and novel drug delivery system for diseases of the colon such as inflammatory bowel disease and colorectal cancer.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Michael A McGuckin
- Translational Research Institute, Inflammatory Disease Biology and Therapeutics Group, Mater Research Institute - The University of Queensland , 37 Kent St., Woolloongabba, Queensland 4102, Australia
| | - Amirali Popat
- Translational Research Institute, Inflammatory Disease Biology and Therapeutics Group, Mater Research Institute - The University of Queensland , 37 Kent St., Woolloongabba, Queensland 4102, Australia
| | | | | |
Collapse
|
19
|
Lee EC, Davis-Poynter N, Nguyen CTH, Peters AA, Monteith GR, Strounina E, Popat A, Ross BP. GAG mimetic functionalised solid and mesoporous silica nanoparticles as viral entry inhibitors of herpes simplex type 1 and type 2 viruses. Nanoscale 2016; 8:16192-6. [PMID: 27604476 DOI: 10.1039/c6nr03878f] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/19/2023]
Abstract
A glycosaminoglycan mimetic was attached to the surface of solid and mesoporous silica nanoparticles to create novel antiviral agents against herpes simplex type 1 and type 2 viruses. The nanoparticles act as viral entry inhibitors that appear to block viral attachment and penetration into susceptible cells.
Collapse
Affiliation(s)
- Edward C Lee
- The University of Queensland, School of Pharmacy, Brisbane, QLD 4072, Australia.
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Dighe SN, Deora GS, De la Mora E, Nachon F, Chan S, Parat MO, Brazzolotto X, Ross BP. Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening. J Med Chem 2016; 59:7683-9. [PMID: 27405689 DOI: 10.1021/acs.jmedchem.6b00356] [Citation(s) in RCA: 110] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Structure-based virtual screening of two libraries containing 567 981 molecules was used to discover novel, selective BuChE inhibitors, which are potentially superior symptomatic treatments in late-stage Alzheimer's disease. Compound 16 was identified as a highly selective submicromolar inhibitor of BuChE (huBuChE IC50 = 0.443 μM) with high permeability in the PAMPA-BBB model. The X-ray crystal structure of huBuChE in complex with 16 revealed the atomic-level interactions and offers opportunities for further development of the series.
Collapse
Affiliation(s)
- Satish N Dighe
- School of Pharmacy, The University of Queensland , Brisbane, Queensland 4072, Australia
| | - Girdhar Singh Deora
- School of Pharmacy, The University of Queensland , Brisbane, Queensland 4072, Australia
| | - Eugenio De la Mora
- Institut de Biologie Structurale (IBS), Université Grenoble Alpes, CEA, CNRS, 38044 Grenoble, France
| | - Florian Nachon
- Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées , 91223 Brétigny sur Orge, France
| | - Stephen Chan
- School of Pharmacy, The University of Queensland , Brisbane, Queensland 4072, Australia
| | - Marie-Odile Parat
- School of Pharmacy, The University of Queensland , Brisbane, Queensland 4072, Australia
| | - Xavier Brazzolotto
- Département de Toxicologie et Risques Chimiques, Institut de Recherche Biomédicale des Armées , 91223 Brétigny sur Orge, France
| | - Benjamin P Ross
- School of Pharmacy, The University of Queensland , Brisbane, Queensland 4072, Australia
| |
Collapse
|
21
|
Rajaram H, Palanivelu MK, Arumugam TV, Rao VM, Shaw PN, McGeary RP, Ross BP. ‘Click’ assembly of glycoclusters and discovery of a trehalose analogue that retards Aβ40 aggregation and inhibits Aβ40-induced neurotoxicity. Bioorg Med Chem Lett 2014; 24:4523-4528. [DOI: 10.1016/j.bmcl.2014.07.077] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2014] [Revised: 07/25/2014] [Accepted: 07/29/2014] [Indexed: 11/29/2022]
|
22
|
Kutyła MJ, Boehm MW, Stokes JR, Shaw PN, Davies NM, McGeary RP, Tuke J, Ross BP. Cyclodextrin-crosslinked poly(acrylic acid): adhesion and controlled release of diflunisal and fluconazole from solid dosage forms. AAPS PharmSciTech 2013; 14:301-11. [PMID: 23307066 PMCID: PMC3581673 DOI: 10.1208/s12249-012-9903-3] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2012] [Accepted: 11/29/2012] [Indexed: 11/30/2022] Open
Abstract
The controlled release of diflunisal and fluconazole from tablets made of novel polymers, poly(acrylic acid) (PAA) crosslinked with either β-cyclodextrin (βCD) or hydroxypropyl-βCD (HPβCD), was investigated and Carbopol 934P (Carbopol) was used as a highly crosslinked PAA for comparison. Diflunisal strongly associates with βCD-PAA and HPβCD-PAA polymers (Ka of 486 and 6,055 M(-1) respectively); thus, it was physically mixed into the conjugates and also precomplexed to identify whether decomplexation has any influence on release kinetics. Fluconazole has poor complexing ability (Ka of 34 M(-1) with HPβCD-PAA); thus, it was only tested as a physical mixture. Swelling and adhesion studies were conducted on all tablet combinations and adhesivity of the CD-PAA polymer tablets was maintained. Diflunisal release was much slower from HPβCD-PAA tablets than from βCD-PAA, suggesting that a higher degree of complexation retards release. The precomplexed diflunisal release was also slower than the physically mixed diflunisal of the corresponding conjugate. The release closely followed zero-order kinetics for HPβCD-PAA, but was more sigmoidal for βCD-PAA and especially Carbopol. Conversely, poorly associating fluconazole released in almost exactly the same way across both polymers and Carbopol, indicating that the release kinetics of poorly associating drugs are not influenced by the presence of cyclodextrins. In view of the varying profiles and release rates shown with diflunisal for the different polymers, the fluconazole data support the concept that adequate complexation can indeed modulate the release kinetics of drugs.
Collapse
Affiliation(s)
- Marguerite J. Kutyła
- />School of Pharmacy, The University of Queensland, Brisbane, QLD 4072 Australia
| | - Michael W. Boehm
- />School of Chemical Engineering, The University of Queensland, Brisbane, QLD 4072 Australia
| | - Jason R. Stokes
- />School of Chemical Engineering, The University of Queensland, Brisbane, QLD 4072 Australia
| | - P. Nicholas Shaw
- />School of Pharmacy, The University of Queensland, Brisbane, QLD 4072 Australia
| | - Nigel M. Davies
- />School of Pharmacy, The University of Queensland, Brisbane, QLD 4072 Australia
| | - Ross P. McGeary
- />School of Pharmacy, The University of Queensland, Brisbane, QLD 4072 Australia
- />School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, QLD 4072 Australia
| | - Jonathan Tuke
- />School of Mathematical Sciences, University of Adelaide, Adelaide, SA 5005 Australia
| | - Benjamin P. Ross
- />School of Pharmacy, The University of Queensland, Brisbane, QLD 4072 Australia
| |
Collapse
|
23
|
Kutyła MJ, Lambert LK, Davies NM, McGeary RP, Shaw PN, Ross BP. Cyclodextrin-crosslinked poly(acrylic acid): Synthesis, physicochemical characterization and controlled release of diflunisal and fluconazole from hydrogels. Int J Pharm 2013; 444:175-84. [DOI: 10.1016/j.ijpharm.2013.01.005] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2012] [Revised: 12/13/2012] [Accepted: 01/02/2013] [Indexed: 10/27/2022]
|
24
|
Popat A, Ross BP, Liu J, Jambhrunkar S, Kleitz F, Qiao SZ. Enzyme-Responsive Controlled Release of Covalently Bound Prodrug from Functional Mesoporous Silica Nanospheres. Angew Chem Int Ed Engl 2012. [DOI: 10.1002/ange.201206416] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
25
|
Popat A, Ross BP, Liu J, Jambhrunkar S, Kleitz F, Qiao SZ. Enzyme-Responsive Controlled Release of Covalently Bound Prodrug from Functional Mesoporous Silica Nanospheres. Angew Chem Int Ed Engl 2012; 51:12486-9. [DOI: 10.1002/anie.201206416] [Citation(s) in RCA: 145] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2012] [Revised: 09/24/2012] [Indexed: 02/01/2023]
|
26
|
|
27
|
Suciati, Lambert LK, Ross BP, Deseo MA, Garson MJ. Phytochemical Study of Fagraea spp. Uncovers a New Terpene Alkaloid with Anti-Inflammatory Properties. Aust J Chem 2011. [DOI: 10.1071/ch10421] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Phytochemical investigation of the stem bark of F. racemosa JACK ex WALL (Loganiaceae) from East Java, Indonesia, has resulted in the isolation of a new alkaloid fagraeoside along with the iridoid glycoside secologanoside. Fagraeoside may be derived from the condensation of secologanin with L-asparagine, and represents a rare example of a terpene alkaloid in which the amino acid component is non-aromatic. Investigation of three additional species of Fagraea provided known lignans, iridoid or secoiridoid glycosides, and flavanol-6-C-glucosides, thus it is likely that iridoid and secoiridoid glucosides are chemotaxonomic markers for the Fagraea genus. Fagraeoside inhibited the production of prostaglandin E2 in 3T3 murine fibroblasts (IC50 ~5.1 µM), and was not cytotoxic to this cell line or to a P388 murine leukaemia cell line. Selected isolated compounds, including fagraeoside, showed low to moderate activity in anti-acetylcholinesterase screening.
Collapse
|
28
|
|
29
|
Ramli S, Gentle IR, Ross BP. Efficient manual Fmoc solid-phase synthesis of the N-terminal segment of surfactant protein B (SP-B(1-25)). Protein Pept Lett 2009; 16:810-4. [PMID: 19601911 DOI: 10.2174/092986609788681706] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The N-terminal 25 residue segment of human surfactant protein B (SP-B(1-25)) was synthesised in 26% yield by manual Fmoc solid-phase peptide synthesis (Fmoc SPPS) using low-loading Fmoc-Gly-Wang resin. Substantial oxidation of Met(21) occurred during the synthesis, and the addition of Bu(4)NBr to a TFA/water/EDT/TIS cleavage cocktail enabled facile reduction of Met(O)(21)-SP-B(1-25) to SP-B(1-25). The methods described herein are generally applicable to the Fmoc SPPS of difficult sequences containing methionine.
Collapse
Affiliation(s)
- Suria Ramli
- The University of Queensland, School of Pharmacy, Qld 4072, Australia
| | | | | |
Collapse
|
30
|
Pham HL, Ross BP, McGeary RP, Shaw PN, Davies NM. Synthesis of cationic derivatives of Quil A and the preparation of cationic immune-stimulating complexes (ISCOMs). Int J Pharm 2009; 376:123-33. [DOI: 10.1016/j.ijpharm.2009.04.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2008] [Revised: 04/06/2009] [Accepted: 04/07/2009] [Indexed: 11/28/2022]
|
31
|
Hussein WM, Ross BP, Landsberg MJ, Lévy D, Hankamer B, McGeary RP. Synthesis of Nickel-Chelating Fluorinated Lipids for Protein Monolayer Crystallizations. J Org Chem 2009; 74:1473-9. [DOI: 10.1021/jo802651p] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Waleed M. Hussein
- The University of Queensland, School of Molecular & Microbial Sciences, Institute for Molecular Bioscience, and School of Pharmacy QLD 4072, Australia, and Institut Curie, UMR CNRS 168, 11 rue P.M.Curie, F-75231 Paris, France
| | - Benjamin P. Ross
- The University of Queensland, School of Molecular & Microbial Sciences, Institute for Molecular Bioscience, and School of Pharmacy QLD 4072, Australia, and Institut Curie, UMR CNRS 168, 11 rue P.M.Curie, F-75231 Paris, France
| | - Michael J. Landsberg
- The University of Queensland, School of Molecular & Microbial Sciences, Institute for Molecular Bioscience, and School of Pharmacy QLD 4072, Australia, and Institut Curie, UMR CNRS 168, 11 rue P.M.Curie, F-75231 Paris, France
| | - Daniel Lévy
- The University of Queensland, School of Molecular & Microbial Sciences, Institute for Molecular Bioscience, and School of Pharmacy QLD 4072, Australia, and Institut Curie, UMR CNRS 168, 11 rue P.M.Curie, F-75231 Paris, France
| | - Ben Hankamer
- The University of Queensland, School of Molecular & Microbial Sciences, Institute for Molecular Bioscience, and School of Pharmacy QLD 4072, Australia, and Institut Curie, UMR CNRS 168, 11 rue P.M.Curie, F-75231 Paris, France
| | - Ross P. McGeary
- The University of Queensland, School of Molecular & Microbial Sciences, Institute for Molecular Bioscience, and School of Pharmacy QLD 4072, Australia, and Institut Curie, UMR CNRS 168, 11 rue P.M.Curie, F-75231 Paris, France
| |
Collapse
|
32
|
Abstract
Suramin is a polysulfonated polyaromatic symmetrical urea. It is currently used to treat African river blindness and African sleeping sickness. Suramin has also been extensively trialed recently to treat a number of other diseases, including many cancers. Here, we examine its modes of action and discuss its structure-activity relationships.
Collapse
Affiliation(s)
- Ross P McGeary
- School of Molecular & Microbial Sciences, The University of Queensland, Brisbane, Qld 4072, Australia.
| | | | | | | | | |
Collapse
|
33
|
Wessling ST, Ross BP, Koda Y, Blanchfield JT, Toth I. Caco-2 cell permeability and stability of two d-glucopyranuronamide conjugates of thyrotropin-releasing hormone. Bioorg Med Chem 2007; 15:4946-50. [PMID: 17498958 DOI: 10.1016/j.bmc.2007.04.042] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2006] [Revised: 03/28/2007] [Accepted: 04/25/2007] [Indexed: 10/23/2022]
Abstract
Caco-2 cell permeability and stability assays were used as an in vitro model to study the intestinal epithelial transport and stability of two analogues of thyrotropin-releasing hormone (TRH; Pyr-His-Pro-NH2). Peptide 1 (Pyr-His-Pro-D-glucopyranuronamide) was more permeable across the Caco-2 cell monolayer compared with the permeability of the parent TRH peptide (Papp=5.10+/-1.89x10(-6) cm/s c.f. Papp=0.147+/-0.0474x10(-6) cm/s respectively). The permeability of peptide 1 was improved threefold by attaching a 2-aminooctanoic acid moiety to the N-terminus to form peptide 2 (2-aminooctanoic acid-Gln-His-Pro-D-glucopyranuronamide) (Papp=16.3+/-2.47x10(-6) cm/s). The half-life for both peptide 1 and peptide 2 was approximately 20 min in a homogenate of Caco-2 cells compared with the half-life of TRH which is approximately 3 min. It was concluded that the permeability of peptides 1 and 2 was enhanced because of their increased stability, while the higher permeability of peptide 2 compared with peptide 1 may be attributed to its increased lipophilicity which results in enhanced passive diffusion.
Collapse
Affiliation(s)
- Susanne T Wessling
- School of Molecular and Microbial Sciences, The University of Queensland, Brisbane, Qld. 4072, Australia
| | | | | | | | | |
Collapse
|
34
|
Pham HL, Ross BP, McGeary RP, Shaw PN, Hewavitharana AK, Davies NM. Saponins from Quillaja saponaria Molina: Isolation, Characterization and Ability to Form Immuno Stimulatory Complexes (ISCOMs). Curr Drug Deliv 2006; 3:389-97. [PMID: 17076641 DOI: 10.2174/156720106778559092] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
ISCOMs have received much attention as vaccine adjuvants due to their immunostimulatory effects. They are colloidal particles typically comprised of phospholipids, cholesterol and Quil A, a crude mixture of saponins extracted from the bark of Quillaja saponaria Molina. We have previously shown that ISCOMs can be prepared by ether injection wherein an ether solution of phospholipids and cholesterol in a mass ratio of 5:2 is injected into a solution of Quil A at a mass ratio of 7 lipids: 3 Quil A. The aim of this study was firstly to isolate and characterise discrete fractions of Quil A and secondly to investigate which of these fractions were able to form ISCOMs by the method of ether injection. Six fractions of Quil A were isolated by semi-preparative reverse phase high performance liquid chromatography (RP-HPLC) and characterised by analytical HPLC, liquid chromatography tandem mass spectrometry (LC-MS) and the qualitative Liebermann-Burchard and Molisch tests for triterpenoids and carbohydrates respectively. ISCOMs were subsequently prepared from the isolated fractions by the method of ether injection and the resulting preparations characterized by photon correlation spectroscopy (PCS) and negative stain transmission electron microscopy (TEM). The molecular weights of the major compounds in the fractions ranged from approximately 1200 to approximately 2300 Da; all fractions tested positive for triterpenoids and saccharides and four of the fractions were identified as QS-7, QS-17, QS-18 and QS-21 by analysis (LC-MS and analytical HPLC). Injection of ether solutions of lipids into aqueous solutions of QS-17, QS-18 or QS-21 all resulted in homogeneous ISCOM dispersions. The combination of lipids and QS-7 by ether injection produced lamellae and liposomes as the prominent structures and a minor amount of ISCOMs. The remaining two hydrophilic, low molecular weight fractions of Quil A did not produce ISCOMs, instead liposomes and helical structures predominated in the samples.
Collapse
Affiliation(s)
- Hoang L Pham
- School of Pharmacy, The University of Queensland, Brisbane, Australia
| | | | | | | | | | | |
Collapse
|
35
|
Ross JA, Ross BP, Rubinsztein‐Dunlop H, McGeary RP. Facile Synthesis of Rhodamine Esters using Acetyl Chloride in Alcohol Solution. SYNTHETIC COMMUN 2006. [DOI: 10.1080/00397910600616818] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
36
|
Cosgrove KL, Bernhardt PV, Ross BP, McGeary RP. Determination of the Anomeric Configurations of 2,3,4,6-Tetra-O-Acetyl-D-Mannopyranosyl Azide. Aust J Chem 2006. [DOI: 10.1071/ch06157] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The structures of 2,3,4,6-tetra-O-acetyl-α-d-mannopyranosyl azide and 2,3,4,6-tetra-O-acetyl-β-d-mannopyranosyl azide were determined using X-ray crystallographic and one-dimensional NOESY techniques.
Collapse
|
37
|
Hayes PY, Ross BP, Thomas BG, Toth I. Polycationic lipophilic-core dendrons as penetration enhancers for the oral administration of low molecular weight heparin. Bioorg Med Chem 2006; 14:143-52. [PMID: 16169233 DOI: 10.1016/j.bmc.2005.08.004] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2005] [Revised: 08/01/2005] [Accepted: 08/01/2005] [Indexed: 10/25/2022]
Abstract
Two polycationic lipophilic-core carbohydrate-based dendrons 2a-b and five polycationic lipophilic-core peptide dendrons 3-6, containing four arginine or lysine terminal residues, were synthesized and then tested in rats as penetration enhancers for the oral delivery of low molecular weight heparin. Better results were obtained with dendrons containing terminal lysine residues than terminal arginine. A significant anti-factor Xa activity was obtained when low molecular weight heparin was coadministered with dendron 5.
Collapse
Affiliation(s)
- Patricia Y Hayes
- Discipline of Chemistry, School of Molecular and Microbial Sciences, and School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia
| | | | | | | |
Collapse
|
38
|
Ross BP, Braddy AC, McGeary RP, Blanchfield JT, Prokai L, Toth I. Micellar aggregation and membrane partitioning of bile salts, fatty acids, sodium dodecyl sulfate, and sugar-conjugated fatty acids: correlation with hemolytic potency and implications for drug delivery. Mol Pharm 2005; 1:233-45. [PMID: 15981926 DOI: 10.1021/mp049964d] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The co-administration of a drug with a penetration enhancer (PE) is one method by which the membrane permeability of a drug can be improved. To facilitate PE design, it is important that the molecular basis of PE toxicity and efficacy be examined, so we investigated the membrane affinity and micellar aggregation of a series of synthetic liposaccharide PEs and correlated these properties with hemolytic potency. The influence of liposaccharide alkyl chain length (nc) on the system was studied, and comparisons were made with conventional PEs such as bile salts, fatty acids, and surfactants. The liposaccharides were each synthesized in eight steps in good overall yield. Their critical micelle concentrations (CMCs) in phosphate-buffered saline ranged from 0.207 to 20.2 mM, and it was found that increasing nc by 2 afforded a 1 order of magnitude decrease in the CMC. Immobilized artificial membrane (IAM) chromatography was used to determine each PE's affinity for biological membranes, and an increase in nc caused a significant increase in the extent of membrane binding. A study of hemolytic activity revealed that liposaccharides with an nc of < or = 12 are the most likely to be biocompatible. The CMC values for all PEs showed a negative correlation with hemolytic potency; however, it was PE monomers, not micelles, that were responsible for the onset of hemolysis. The affinity of all enhancers for the IAM displayed a positive correlation with hemolytic potency, and therefore, IAM chromatography can be used to predict PE hemolytic activity. It was concluded that the biocompatibility of liposaccharides can be modulated by minor alterations in nc.
Collapse
Affiliation(s)
- Benjamin P Ross
- School of Molecular and Microbial Sciences and School of Pharmacy, University of Queensland, Brisbane, Queensland 4072, Australia
| | | | | | | | | | | |
Collapse
|
39
|
Abstract
A review with 93 references. Heparins are high molecular weight, hydrophilic polyanions, which are unstable under acidic conditions; and therefore they exhibit poor oral bioavailability. Consequently they must be administered via the parenteral route which is expensive, inconvenient, and limits use by outpatients. The development of an oral form of heparin is warranted. This review examined the literature, mostly published between January 2000 and January 2005, pertaining to the gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers. A lipidization strategy that was examined involved conjugation of low molecular weight heparin with deoxycholic acid. The majority of studies examined the ability of different formulations, typically utilizing penetration enhancers, to improve heparin bioavailability. The penetration enhancers used included fatty acids, Labrasol, Gelucire 44/14, polycationic lipophilic-core dendrons, saponins, mono-N-carboxymethyl chitosan, Carbopol 934P, a combination of thiolated polycarbophil and glutathione, polymeric nanoparticles, polymeric microparticles, sodium N-[8-(2-hydroxybenzoyl) amino]caprylate (SNAC), and sodium N-[10-(2-hydroxybenzoyl)amino]decanoate (SNAD). The variety of models used and doses of heparin/penetration enhancers applied, however, made it difficult to compare the results between studies. Nevertheless, all of the reviewed drug delivery systems showed therapeutic value and confirmation of the promising results obtained from animal studies, by progression to clinical trials, is necessary. Overall, progress has been made in the quest for an oral heparin formulation.
Collapse
Affiliation(s)
- Benjamin P Ross
- School of Molecular and Microbial Sciences, The University of Queensland, Brisbane, Queensland 4072 Australia
| | | |
Collapse
|
40
|
Ross BP, DeCruz SE, Lynch TB, Davis-Goff K, Toth I. Design, Synthesis, and Evaluation of a Liposaccharide Drug Delivery Agent: Application to the Gastrointestinal Absorption of Gentamicin. J Med Chem 2004; 47:1251-8. [PMID: 14971905 DOI: 10.1021/jm030474j] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The design, synthesis, and evaluation of a liposaccharide (11) for use as an agent to enhance the gastrointestinal absorption of charged, hydrophilic drugs with poor membrane permeability is reported. 11 was designed to possess both surfactant and ion-pairing properties and was conveniently synthesized from d-glucuronic acid (2) and N-Boc-lipoamino acid (5) precursors in eight steps in good yield. Isothermal titration microcalorimetry was used to determine the critical micelle concentration of 11 (in PBS) to be 2.09 +/- 0.01 mM with an enthalpy of demicellization of 4.91 +/- 0.11 kJ/mol. The ability of 11 to enhance the gastrointestinal absorption of the aminoglycoside antibiotic gentamicin (1), a hydrophilic polycation with negligible oral bioavailability, was assessed in vivo using rats. Rats dosed orally with a mixture of 11 (100 mg/kg) and 1 (60 mg/kg) had a statistically significant (P < or = 0.034) increase in Cmax, AUC120, and percent absolute bioavailability (F) compared to control 1 (60 mg/kg) alone. The highest bioavailability (F = 9.1 +/- 2.0%) was achieved by dosing with the mixture 11 (100 mg/kg) and 1 (15 mg/kg). This represents a 6-fold increase in bioavailability compared to the control (F = 1.4 +/- 0.3%). These results suggest that the molar ratio of 1:11 may be critical in optimizing the delivery system, a finding ascribed in part to the ion-pairing properties of 11. The effect of 11 on the gastrointestinal mucosa was assessed using light microscopy to examine tissue samples from rats used in the pharmacokinetic study. No morphological changes were found in either the esophagi or duodena of the rats examined. One rat dosed with 11 (100 mg/kg) and 1 (60 mg/kg) exhibited slight gastric erosion, which could be attributed to 11.
Collapse
Affiliation(s)
- Benjamin P Ross
- School of Molecular and Microbial Sciences, The University of Queensland, Brisbane, Queensland 4072, Australia
| | | | | | | | | |
Collapse
|
41
|
Wong AK, Ross BP, Chan YN, Artursson P, Lazorova L, Jones A, Toth I. Determination of transport in the Caco-2 cell assay of compounds varying in lipophilicity using LC-MS: enhanced transport of Leu-enkephalin analogues. Eur J Pharm Sci 2002; 16:113-8. [PMID: 12128164 DOI: 10.1016/s0928-0987(02)00078-7] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
PURPOSE To synthesize a number of analogues of Leu-enkephalin with different lipophilicities and to develop an LC-MS method for determining the Caco-2 cell permeability values of these compounds. METHODS A number of sugar and sugar plus lipoamino acid analogues of Leu-enkephalin were synthesized by solid-phase and solution methods. An LC-MS method was developed for analyzing the Caco-2 cell assay samples and validated against the traditional method using radiolabelled compounds. RESULTS A sensitive and specific LC-MS assay was developed. Standard curves were linear in the range of 0.025-5 microM. Apparent permeability values determined by LC-MS and liquid scintillation counter were identical, for both a hydrophilic drug, cephalexin and a lipophilic Leu-enkaphalin analogue. Caco-2 permeability values for the analogues of Leu-enkephalin were determined and it was found that attachment of sugar or sugar and lipoamino acid to the Leu-enkephalin peptide resulted in an increase in the apparent permeability values compared to the native peptide, which was not transported across the Caco-2 cell monolayers. CONCLUSIONS A rapid, generic LC-MS method for analyzing a range of compounds was developed. Attachment of a sugar or sugar and lipoamino acid to Leu-enkephalin improves the apparent permeability across Caco-2 cell monolayers.
Collapse
Affiliation(s)
- Allan K Wong
- School of Pharmacy, The University of Queensland, 4072, St. Lucia, Australia
| | | | | | | | | | | | | |
Collapse
|
42
|
Bernhardt PV, Carman RM, Ross BP. Aust J Chem 2000; 53:611. [DOI: 10.1071/ch00022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|